Guest Editorial Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories April 24, 2026Vol.52 No.16By Edward Miskie
Guest Editorial Forty years after Chernobyl: Little evidence to show that radiation released from the accident increased cancers globally April 24, 2026Vol.52 No.16By Robert Peter Gale
Health EquityRegulatory News Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancerA kit for at-home unsupervised self-collection clears FDA finish line April 17, 2026Vol.52 No.15By Claire Marie Porter
Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OSPanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” April 17, 2026Vol.52 No.15By Jacquelyn Cobb
Cancer History ProjectEditorial Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budgetFox Chase’s Winn contemplates Crossroads 2.0 April 17, 2026Vol.52 No.15By Paul Goldberg
Guest Editorial Most Favored Nation drug pricing could put China on top April 17, 2026Vol.52 No.15By John Stanford
Sponsored Bridging communication and genomics: A path toward equitable cancer care April 17, 2026Vol.52 No.15By Stacy W. Gray
Conversation with The Cancer Letter Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdyNCI expects record-breaking spending on extramural research April 10, 2026Vol.52 No.14By Claire Marie Porter and Paul Goldberg
Guest Editorial America needs a new blueprint for the National Cancer ProgramFirst step: Develop Version 2.0 of Paul Calabresi’s “Cancer at a Crossroads” April 10, 2026Vol.52 No.14By Robert A. Winn
California state-funded institute scraps selection process that put cancer projects at a disadvantageCancer researchers are resubmitting applications to the California Institute for Regenerative Medicine April 10, 2026Vol.52 No.14By Sara Willa Ernst
